Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Interpace Biosciences is focused on creating innovative solutions for personalized medicine through the development and commercialization of molecular diagnostic tests, especially in areas of oncology.

Our vision is to become the leader in molecular diagnostics, offering personalized health care solutions for the optimal physical, emotional and mental well-being of patients.

Interpace Biosciences has been the proud recipient of several notable awards, including a Grand Prize at the 2017 Bio-IT World Datathon and the 2018 WhiteHat Investor Challenge award. The company has also been recognized by Frost & Sullivan's End-User Value Creation Award.